Protara Therapeutics (TARA) announced that data from THRIVE-1, a prospective, observational study evaluating the prevalence of choline ...

Apart from TARA-002, Protara’s clinical pipeline comprises an investigational IV phospholipid substrate replacement therapy, IV Choline Chloride, which is being developed as a source of choline ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases ...

Concurrently, Protara Therapeutics reached alignment with the FDA on a registrational path forward for intravenous (IV) Choline Chloride. The company had previously been pursuing an indication in ...